Tradipitant

Last updated

Tradipitant
LY686017.svg
Clinical data
Trade names Nereus
Other namesVLY-686, LY686017
AHFS/Drugs.com nereus
License data
Routes of
administration 		By mouth
Drug class Neurokinin NK1 antagonist
ATC code
  • None
Legal status
Legal status
Identifiers
  • (2-(1-(3,5-Bis(trifluoromethyl)benzyl)-5-(pyridin-4-yl)-1H-1,2,3-triazol-4-yl)pyridin-3-yl)(2-chlorophenyl)methanone
CAS Number
PubChem CID
DrugBank
ChemSpider
UNII
KEGG
ChEMBL
CompTox Dashboard (EPA)
Chemical and physical data
Formula C28H16ClF6N5O
Molar mass 587.91 g·mol−1
3D model (JSmol)
  • Clc1ccccc1C(=O)c2c(nccc2)c3nnn(c3c4ccncc4)Cc5cc(cc(c5)C(F)(F)F)C(F)(F)F
  • InChI=1S/C28H16ClF6N5O/c29-22-6-2-1-4-20(22)26(41)21-5-3-9-37-23(21)24-25(17-7-10-36-11-8-17)40(39-38-24)15-16-12-18(27(30,31)32)14-19(13-16)28(33,34)35/h1-14H,15H2
  • Key:CAVRKWRKTNINFF-UHFFFAOYSA-N

Tradipitant, sold under the brand name Nereus, is a medication used as prevention of vomiting induced by motion (motion sickness). [1] It is a neurokinin 1 receptor antagonist. [1] It works by blocking substance P, a small signaling molecule. [1] VLY-686 was purchased by Vanda Pharmaceuticals from Eli Lilly and Company in 2012. [2]

Contents

Tradipitant was approved for medical use in the United States in December 2025. [3]

Medical uses

Tradipitant is indicated for the prevention of vomiting induced by motion. [1]

Society and culture

Tradipitant was approved for medical use in the United States in December 2025. [4]

Names

Tradipitant is the international nonproprietary name. [5]

Tradipitant is sold under the brand name Nereus. [1]

References

  1. 1 2 3 4 5 6 https://www2.assets.vandapharma.com/Nereus/Prescribing_Information_NDA_220152_Nereus.pdf
  2. ↑ "Company Overview of Eli Lilly & Co., Worldwide License to Develop and Commercialize VLY-686". Bloomberg Business. Retrieved 16 November 2015.
  3. ↑ "Novel Drug Approvals for 2025". U.S. Food and Drug Administration (FDA). 2 January 2026. Retrieved 10 January 2026.
  4. ↑ "Vanda Pharmaceuticals Announces FDA Approval of Nereus (tradipitant) for the Prevention of Vomiting Induced by Motion: A Historic Scientific Milestone in the Prevention of Motion Sickness" (Press release). Vanda Pharmaceuticals. 30 December 2025. Retrieved 10 January 2026– via PR Newswire.
  5. ↑ World Health Organization (2015). "International nonproprietary names for pharmaceutical substances (INN): recommended INN: list 73". WHO Drug Information. 29 (1). hdl: 10665/331088 .


This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.